USPTO serial 98910311
INSITRO
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- ZELLNER, SIERRA E
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with INSITRO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,545*
Plus Government fees of $750
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
South San Francisco, CA, US
South San Francisco, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ted D. Karr
Ted D. Karr Berkeley Law & Technology Group LLP7710 Rialto Blvd, Suite 100Austin, TX 78735United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical and biological reagents for scientific research, drug discovery, and drug development; laboratory chemicals and solutions for research purposes, excluding those for medical use, namely, reagents supporting artificial intelligence-driven workflows and machine learning applications | ACTIVE | — |
| 005 | Pharmaceutical preparations and substances for human and veterinary use for the treatment and prevention of diseases, namely, human metabolic diseases, human neurological diseases, human ophthalmological diseases, and human genetic diseases | ACTIVE | — |
| 009 | Laboratory automation systems comprising scientific laboratory research apparatus for the automated screening of cells and molecules for understanding disease causes and mechanisms, and recorded software for controlling the apparatus, for scientific research, drug discovery, and drug development; Artificial intelligence (AI) and machine learning (ML) platforms, namely, recorded software platforms for experimental data generation for scientific and laboratory applications for scientific and medical research; digital health solutions, namely, downloadable software for integrating data-driven medical insights | ACTIVE | — |
| 042 | Scientific and technological research and development services in the fields of drug discovery, pharmaceutical development, and biotechnology; Platform as a Service featuring artificial intelligence (AI) and machine learning (ML) software platforms for drug discovery, pharmaceutical development, and biotechnology for scientific and medical research; Development of computer software, for drug discovery, genomics, and data analysis; laboratory research services in the field of pharmaceuticals, using automation, high-throughput experimentation, and data modeling; software as a service (SaaS) featuring software for AI-powered drug discovery, predictive modeling, and biological data analysis; consulting services in computational biology and AI-driven drug discovery; Medical research services and consulting services in the field of medical research; drug discovery and development support services from a medical perspective, namely, pharmaceutical drug development services; providing medical information and consultancy, namely, providing information and consulting in the field of medical research, related to therapeutic research and development; provision of medicine in the field of diseases, namely, developing treatments for unmet medical needs | ACTIVE | — |
| 044 | Personalized medicine services, namely, making recommendations for medical diagnostic tests and therapeutic recommendations to patients; healthcare services utilizing artificial intelligence for disease prediction, patient stratification, and management; medical analysis services for diagnostic and treatment purposes of patients; healthcare services; medical treatment services for diseases; healthcare advisory services; pharmaceutical advice; medical clinic services; medical advice for individuals with diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Insitro, Inc.
- Other trademarks owned by Insitro, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named INSITRO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 17, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 15, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 15, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 15, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 20, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 25, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 25, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 19, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 23, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 23, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 23, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 23, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 23, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 20, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 20, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 20, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 27, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Aug 27, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jun 1, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 1, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 1, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 30, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 28, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 18, 2024 | NWAP | NEW APPLICATION ENTERED | — |